NASDAQ OMX

Bermuda Principles event merges science and business

Dela

HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research.

Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa.  Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors.

"I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to promote the Bermuda Principles document that was created at a conference that took place here back in 1996, and it's awesome to realise that thanks to the work we've done, more Bermudians, including our MPs, know about this now. It's an important legacy, and we should all be proud of the role Bermuda has played in genetics history."

In 1996, a scientific milestone occurred in Bermuda, after US and UK scientists met on the island to negotiate the completion of the Human Genome Project. In a landmark agreement, they decided gene sequences developed by numerous private labs would be made publicly available worldwide to advance scientific research. The agreement, called "The Bermuda Principles," contributed to the pace and reach of scientific research that followed.

This year's conference pays tribute to that history, while forging forward with a contemporary agenda of sessions dedicated to topics ranging from bioinformatics, regulation, technologies, therapeutics, gene splicing and disease, and commercialisation of university research. Speakers include keynote Adrian Krainer, Professor at Cold Spring Harbor Laboratory, New York; Jean Beggs, Fellow of the Royal Society and Professor, Edinburgh; Daniel Larson, of the Center for Cancer Research, Maryland; Franco Pagani, of the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy; and Robin Reed, Professor of Cell Biology, Harvard Medical School.

One of the conference highlights will focus on how to commercialise scientific ideas, leveraging investment to turn them into viable businesses.

"As a researcher at a university, I had to quickly realise that what I was doing today could become a business venture tomorrow," said Weldon, who is also creating a foundation to promote science in the Bermuda community. "I have had to get my own head around commercialisation. In academia, we're taught to do experiments and publish, but sometimes that prevents you from turning an idea into a profitable venture. That's why I wanted to include this topic in the conference."

The closing session will feature the BDA's consultant for Emerging Technologies John Narraway and others discussing the island's attraction to biotech investors as a blue-chip international finance centre. It's one of numerous public-engagement events linking science to education, healthcare and business that will see conference participation by students, teachers, and medical and corporate professionals.

"Bermuda has long been the domicile for many established and well-known biotech companies," noted Narraway. "We see a conference like this as an opportunity to build a new ecosystem for early-stage biotech and life-science ventures. The BDA is participating in the event as a way to connect with these researchers and show the value the island can bring to those looking to transform their research into a commercial opportunity and licensable product."

Thursday night will feature a Bermuda Youth Parliament debate on the research use of immortal HeLa cells derived from a cancer patient. The event, to be live-streamed on Facebook, Twitter and Instagram, will be opened by Dr. Daniel Ford, Professor of Medicine at the Johns Hopkins University School of Medicine. Bermuda MPs have been invited to attend and winning students will receive smart phones courtesy of Digicel.

On Friday, local high-schoolers will carry out a genetic-engineering experiment using kits provided by Amino Labs in which colourful jellyfish DNA will be added to bacteria.

Saturday afternoon will see science teachers from local schools join doctors and other professionals for a panel discussion on integrating research into healthcare and education curricula.

The leading partner of the conference is Bank of Bermuda Foundation. Sponsors include: Bermuda Business Development Agency (BDA), Bermuda Technology Initiative, Bermuda Tourism Authority (BTA), De Montfort University, New England BioLabs, RNA Society, Island Press and Amino Labs.

MEDIA CONTACT:

Rosemary Jones
Head of Communications & Marketing
rosemary@bda.bm
441 278-6558
441 337-4696

CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business here smooth and beneficial.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0493acf0-aeec-4be0-88a2-3e42938c6112




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bermuda Business Development Agency (BDA) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Hoylu AB: UNITED STATES ARMY SELECTS HOYLU FOR DIGITAL COLLABORATION SOLUTIONS26.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 26, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Army has selected Hoylu Software and the large format HoyluWall system as a digital workspace tool for workspace collaboration, process planning and ideation. Hoylu software will be used to modify, save, print and communicate between teams at remote locations and allow for collaborative analysis. The order will be delivered in Q3 2018 and represents a deal value of SEK 528,000 in product and software revenue and presents ongoing opportunities to expand within the government sector. This system will be installed at the Picatinny Arsenal in New Jersey, the US Army's primary R&D arm for armament and munitions systems. Picatinny Arsenal is the Joint Center of Excellence for Guns and Ammunition, providing products and services to all branches of the U.S. military. Picatinny Arsenal has partnerships with a variety of universities and industry partners, involving them i

Hoylu AB: USA:s armé väljer Hoylu för digitala samarbetslösningar26.9.2018 08:30Pressmeddelande

Malmö, Sverige, 26:e september 2018 - Hoylu, ett ledande företag inom digitala samarbetslösningar tillkännagav idag att USA:s armé har valt Hoylus mjukvara och storformats Hoylu Wall-system som verktyg för digitalt samarbete, delade arbetsytor, processplanering och idégenerering. Hoylus mjukvara kommer användas till att modifiera, spara, skriva ut och stödja samarbete mellan team på olika platser samt möjliggöra kollaborativ analys. Ordern kommer levereras under tredje kvartalet 2018 och har ett sammanlagt värde på SEK 528 000 för hård- och mjukvara. Ordern visar på ökande möjligheter att växa inom statlig och offentlig verksamhet. Systemet kommer installeras på Picatinny Arsenal i New Jersey, USA:s armés primära R&D-enhet för vapen- och ammunitionssystem. Picatinny Arsenal är ett s.k. "Joint Center of Excellence" för vapen och ammunition och de tillhandahåller produkter och tjänster åt alla grenar av USA:s armé. Picatinny Arsenal har också samarbeten med en mängd olika universitet och

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum